ARTICLEAdenoid Cystic Carcinoma Part II Assessing Surgical and Nonsurgical Treatments and ManagementSt. Clair, Eric G. MD; DeMonte, Franco MDAuthor Information Dr. St. Clair is Assistant Professor, Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA; and Dr. DeMonte is Professor and Mary Beth Pawelek Chair in Neurosurgery, Department of Neurosurgery—Unit 442, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; E-mail: [email protected]. The authors have disclosed that the use of gefitinib, lapatinib, cetuximab, and imatinib for treatment of adenoid cystic carcinoma as discussed in this article has not been approved by the U.S. Food and Drug Administration. All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc. designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Association of Neurological Surgeons attests that this educational activity has been recognized for co-sponsored/endorsement for 1.5 Category 1 CME credits of the American Association of Neurological Surgeon's Continuing Education Award in Neurosurgery. To earn CME credit, you must read the CME article and complete the quiz and evaluation on the enclosed form, answering at least 70% of the quiz questions correctly. This activity expires on January 14, 2011. Category: Tumor From the Editor, I am very pleased to announce that retroactive to Volume 25, Issue 1, the American Association of Neurological Surgeons attests that this educational activity has been recognized for co-sponsored/endorsement for 1.5 Category 1 CME credits of the American Association of Neurological Surgeons' Continuing Education Award in Neurosurgery. Contemporary Neurosurgery: January 15, 2010 - Volume 32 - Issue 1 - p 1-6 doi: 10.1097/01.CNE.0000368170.11015.3d Buy CME Test Metrics © 2010 Lippincott Williams & Wilkins, Inc.